InMed Pharmaceuticals Inc.

NasdaqCM:INM

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

Location

Canada

Market Cap

USD 3.03 M

Share Price

USD 2.51

Avg Daily Volume

1,309,407

Change (1 day)

6.36%

Change (1 year)

-54.53%

Change (YTD)

-47.05%

InMed Pharmaceuticals Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025

InMed Pharmaceuticals Inc. EBITDA is NA for the Trailing 12 Months (TTM) ending March 31, 2025. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

InMed Pharmaceuticals Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -15.82 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: INM

InMed Pharmaceuticals Inc.

CEO	Mr. Eric A. Adams B.S. Chem., M.I.B.
IPO Date	May 5, 2014
Location	Canada
Headquarters	815 West Hastings Street
Employees	13
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials

Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.